vs
Side-by-side financial comparison of HCI Group, Inc. (HCI) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
HCI Group, Inc. is the larger business by last-quarter revenue ($246.2M vs $177.4M, roughly 1.4× Pacira BioSciences, Inc.). HCI Group, Inc. runs the higher net margin — 39.7% vs 1.6%, a 38.0% gap on every dollar of revenue. On growth, HCI Group, Inc. posted the faster year-over-year revenue change (52.1% vs 5.0%). Over the past eight quarters, HCI Group, Inc.'s revenue compounded faster (9.2% CAGR vs -0.2%).
HCI Equity Partners is a Washington, DC–based private equity firm with an additional office in Chicago, Illinois.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
HCI vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $246.2M | $177.4M |
| Net Profit | $97.7M | $2.9M |
| Gross Margin | — | — |
| Operating Margin | 58.5% | 3.9% |
| Net Margin | 39.7% | 1.6% |
| Revenue YoY | 52.1% | 5.0% |
| Net Profit YoY | 3679.2% | — |
| EPS (diluted) | $7.29 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $246.2M | $196.9M | ||
| Q3 25 | $216.3M | $179.5M | ||
| Q2 25 | $221.9M | $181.1M | ||
| Q1 25 | $216.4M | $168.9M | ||
| Q4 24 | $161.9M | $187.3M | ||
| Q3 24 | $175.3M | $168.6M | ||
| Q2 24 | $206.2M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $97.7M | — | ||
| Q3 25 | $65.5M | $5.4M | ||
| Q2 25 | $66.2M | $-4.8M | ||
| Q1 25 | $69.7M | $4.8M | ||
| Q4 24 | $2.6M | — | ||
| Q3 24 | $5.7M | $-143.5M | ||
| Q2 24 | $54.1M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 58.5% | 1.2% | ||
| Q3 25 | 41.9% | 3.5% | ||
| Q2 25 | 42.5% | 4.7% | ||
| Q1 25 | 46.4% | 1.2% | ||
| Q4 24 | 3.6% | 13.2% | ||
| Q3 24 | 8.0% | -82.8% | ||
| Q2 24 | 36.9% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | 39.7% | — | ||
| Q3 25 | 30.3% | 3.0% | ||
| Q2 25 | 29.8% | -2.7% | ||
| Q1 25 | 32.2% | 2.8% | ||
| Q4 24 | 1.6% | — | ||
| Q3 24 | 3.2% | -85.1% | ||
| Q2 24 | 26.2% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $7.29 | $0.05 | ||
| Q3 25 | $4.90 | $0.12 | ||
| Q2 25 | $5.18 | $-0.11 | ||
| Q1 25 | $5.35 | $0.10 | ||
| Q4 24 | $0.32 | $0.38 | ||
| Q3 24 | $0.52 | $-3.11 | ||
| Q2 24 | $4.24 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.2B | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.0B | $653.9M |
| Total Assets | $2.5B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $1.2B | $238.4M | ||
| Q3 25 | $987.9M | $246.3M | ||
| Q2 25 | $947.2M | $445.9M | ||
| Q1 25 | $754.5M | $493.6M | ||
| Q4 24 | $532.5M | $484.6M | ||
| Q3 24 | $518.8M | $453.8M | ||
| Q2 24 | $445.8M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $1.0B | $693.1M | ||
| Q3 25 | $821.8M | $727.2M | ||
| Q2 25 | $758.6M | $757.8M | ||
| Q1 25 | $522.7M | $798.5M | ||
| Q4 24 | $453.3M | $778.3M | ||
| Q3 24 | $455.3M | $749.6M | ||
| Q2 24 | $447.3M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $2.5B | $1.3B | ||
| Q3 25 | $2.3B | $1.3B | ||
| Q2 25 | $2.4B | $1.5B | ||
| Q1 25 | $2.3B | $1.6B | ||
| Q4 24 | $2.2B | $1.6B | ||
| Q3 24 | $2.0B | $1.5B | ||
| Q2 24 | $1.9B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $444.4M | — |
| Free Cash FlowOCF − Capex | $440.8M | — |
| FCF MarginFCF / Revenue | 179.0% | — |
| Capex IntensityCapex / Revenue | 1.5% | — |
| Cash ConversionOCF / Net Profit | 4.55× | — |
| TTM Free Cash FlowTrailing 4 quarters | $771.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $444.4M | $43.7M | ||
| Q3 25 | $26.7M | $60.8M | ||
| Q2 25 | $145.0M | $12.0M | ||
| Q1 25 | $162.0M | $35.5M | ||
| Q4 24 | $331.8M | $33.1M | ||
| Q3 24 | $104.1M | $53.9M | ||
| Q2 24 | $-29.0M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $440.8M | $43.5M | ||
| Q3 25 | $25.9M | $57.0M | ||
| Q2 25 | $144.5M | $9.3M | ||
| Q1 25 | $160.3M | $26.9M | ||
| Q4 24 | $327.8M | $31.0M | ||
| Q3 24 | $103.2M | $49.8M | ||
| Q2 24 | $-30.1M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | 179.0% | 22.1% | ||
| Q3 25 | 12.0% | 31.7% | ||
| Q2 25 | 65.1% | 5.1% | ||
| Q1 25 | 74.1% | 15.9% | ||
| Q4 24 | 202.5% | 16.6% | ||
| Q3 24 | 58.9% | 29.6% | ||
| Q2 24 | -14.6% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 1.5% | 0.1% | ||
| Q3 25 | 0.4% | 2.2% | ||
| Q2 25 | 0.2% | 1.5% | ||
| Q1 25 | 0.8% | 5.1% | ||
| Q4 24 | 2.5% | 1.1% | ||
| Q3 24 | 0.5% | 2.4% | ||
| Q2 24 | 0.5% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | 4.55× | — | ||
| Q3 25 | 0.41× | 11.20× | ||
| Q2 25 | 2.19× | — | ||
| Q1 25 | 2.32× | 7.37× | ||
| Q4 24 | 128.41× | — | ||
| Q3 24 | 18.33× | — | ||
| Q2 24 | -0.54× | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HCI
| Insurance Operation | $218.3M | 89% |
| Reciprocal Exchange Operation | $27.0M | 11% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
